#Windward_Bio
LightNews LightNews
newsen.bsky.social
Windward Bio Achieves Successful Nasdaq Listing as Biotechnology Leader#Shanghai#USA#Windward_Bio#Nasdaq_Listing#Qiming_Venture
Windward Bio Achieves Successful Nasdaq Listing as Biotechnology Leader
Windward Bio, a promising biotech firm, has made its successful debut on Nasdaq, marking a significant milestone for chronic disease treatments with innovative therapies.
third-news.com
November 14, 2026 at 4:25 PM
newsen.bsky.social
Windward Bio Achieves Milestone with Nasdaq Listing to Transform Immunology Treatments#China#Shanghai#NASDAQ#Windward_Bio#Qiming_Venture_Partners
Windward Bio Achieves Milestone with Nasdaq Listing to Transform Immunology Treatments
Windward Bio goes public on Nasdaq, marking a significant advancement in immunology biotech. Their innovative treatments target chronic inflammatory diseases.
third-news.com
November 14, 2026 at 3:30 AM
newsen.bsky.social
Windward Bio's Latest Results Show Promise for New Asthma Treatment in Phase 2 Trials#USA#Chengdu#Windward_Bio#SKB378#Asmtha_Treatment
Windward Bio's Latest Results Show Promise for New Asthma Treatment in Phase 2 Trials
Windward Bio’s Phase 2 results demonstrate the effectiveness of SKB378/WIN378 in treating asthma, paving the way for Phase 3 studies.
third-news.com
September 8, 2026 at 12:17 PM
newsen.bsky.social
Kelun-Biotech and Windward Bio Begin Phase 2 Study for COPD Treatment SKB378/WIN378#China#Chengdu#Kelun-Biotech#Windward_Bio#SKB378
Kelun-Biotech and Windward Bio Begin Phase 2 Study for COPD Treatment SKB378/WIN378
Kelun-Biotech and Windward Bio have kicked off the Phase 2 SIRIUS trial for SKB378/WIN378, a promising COPD treatment. This study aims to offer new hope to millions of COPD patients worldwide.
third-news.com
June 9, 2026 at 12:44 PM
newsen.bsky.social
Kelun-Biotech Partners with Windward Bio for Phase 2 Asthma Trial of SKB378/WIN378#China#Chengdu#Kelun-Biotech#Windward_Bio#SKB378
Kelun-Biotech Partners with Windward Bio for Phase 2 Asthma Trial of SKB378/WIN378
Kelun-Biotech announces the initiation of a Phase 2 clinical trial for SKB378/WIN378, a novel treatment for asthma in partnership with Windward Bio.
third-news.com
July 23, 2025 at 1:46 PM
newsen.bsky.social
Kelun-Biotech and Windward Bio Forge Strategic Collaboration for TSLP Monoclonal Antibody Development#China#Chengdu#Kelun-Biotech#Windward_Bio#TSLP_Antibody
Kelun-Biotech and Windward Bio Forge Strategic Collaboration for TSLP Monoclonal Antibody Development
Sichuan Kelun-Biotech Biopharmaceutical Co. has partnered with Windward Bio to develop SKB378/HBM9378, a promising monoclonal antibody targeting severe respiratory diseases.
third-news.com
January 11, 2025 at 8:45 AM
newsen.bsky.social
Novo Holdings Fuels Windward Bio's $200 Million Launch for Asthma Treatments#Novo_Holdings#Denmark#Copenhagen#Windward_Bio#WIN378
Novo Holdings Fuels Windward Bio's $200 Million Launch for Asthma Treatments
Novo Holdings has invested in a $200M Series A financing for Windward Bio, aiming to develop innovative treatments for asthma and COPD with a focus on long-acting therapies.
third-news.com
January 10, 2025 at 2:37 PM
newsen.bsky.social
Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment#None#HBM9378#Windward_Bio#Harbour_BioMed
Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment
Harbour BioMed and Windward Bio enter a license agreement for HBM9378, an innovative antibody aimed at treating immunological diseases, signaling promising medical advancements.
third-news.com
January 10, 2025 at 1:27 PM